 |
|
|
|
 |
|
|
| Article 1 to 5 out of 5 concerning Galapagos Genomics BV
|
-
Galapagos, Amsterdam Molecular Therapeutics, Netherlands Institute for Brain Research and Vrije Universiteit Amsterdam cooperate
(09/19/2005)
Galapagos, Amsterdam Molecular Therapeutics B.V. (AMT), the Netherlands Institute for Brain Research (NIBR), and the Vrije Universiteit Amsterdam (VUA) announce their collaboration to develop innovative treatments for acute spinal cord and ...
-
Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University collaborate in arthritis drug discovery program
(08/11/2005)
Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University announced the formation of a four-way collaboration to pursue a small molecule drug discovery program in the area of arthritis. The collaboration, funded in part by an IS ...
-
Galapagos and Celera Genomics sign gene function analysis agreement
(06/21/2005)
Galapagos announced that it has entered into a services agreement with Celera Genomics Group, an Applera Corporation business. Under the agreement, Galapagos' services division Galadeno will provide technology and adenoviral reagents enabling Celera ...
-
Cystic Fibrosis Foundation Therapeutics and Galapagos Initiate Alliance to Discover Drug Targets
(04/18/2005)
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), and Galapagos have initiated a two-year target discovery alliance. The organizations will apply Galapagos' adenoviral siRNA (SilenceSelect®) and cDNA (FLeXSelect®) collections and expertise in ...
-
Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos Genomics NV
(11/10/2004)
Galapagos Genomics announced that it has reached a research milestone in its osteoporosis discovery program with Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth. Within the program, which was initiated November 2003, Galapagos has used ...
Additional information
Galapagos Genomics BV
Leiden, Netherlands
Company
|
|
|
|
|
|
Top
